[
    [
        {
            "time": "2018-01-02",
            "original_text": "Medical Marijuana Stocks to Cure Your Portfolio",
            "features": {
                "keywords": [
                    "Medical",
                    "Marijuana",
                    "Stocks",
                    "Cure",
                    "Portfolio"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Medical Marijuana Stocks to Cure Your Portfolio",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Formulary",
                    "Listings",
                    "Hepatitis",
                    "C",
                    "Treatment",
                    "MAVIRET"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Novartis Resubmits BLA to FDA for Biosimilar of Neulasta",
            "features": {
                "keywords": [
                    "Novartis",
                    "Resubmits",
                    "BLA",
                    "FDA",
                    "Biosimilar",
                    "Neulasta"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis Resubmits BLA to FDA for Biosimilar of Neulasta",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]